SCHEMBL15037258

SCHEMBL15037258

CC(C)(C)c1ccc(C(=O)N[C@@H](Cc2ccc(-c3noc(-c4ccc(Oc5ccccc5)cc4)n3)cc2)C(=O)O)cc1

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MCHR1 Q99705 2/20 0.54
▸ TPH1 P17752 3/20 0.50
▸ PPARD Q03181 3/20 0.49
▸ PPARA Q07869 3/20 0.49
▸ PPARG P37231 1/20 0.49
▸ S1PR4 O95977 2/20 0.47
▸ S1PR1 P21453 2/20 0.47
▸ S1PR5 Q9H228 2/20 0.47
▸ S1PR3 Q99500 1/20 0.47
▸ ACACB O00763 5/20 0.46
▸ SMPD1 P17405 1/20 0.45
▸ PTPN1 P18031 1/20 0.44
▸ GPR132 Q9UNW8 1/20 0.44
▸ MME P08473 1/20 0.44
▸ ACE P12821 1/20 0.44
▸ CPA1 P15085 1/20 0.44
▸ ACE2 Q9BYF1 1/20 0.44
▸ HDAC4 P56524 2/20 0.44
▸ HDAC6 Q9UBN7 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15037252 0.93 S1PR4 (0.52) TPH1PPARDPPARAPPARGS1PR4
SCHEMBL22449247 0.92 S1PR4 (0.54) TPH1PPARDPPARAPPARGS1PR4
SCHEMBL15037155 0.92 S1PR4 (0.54) TPH1PPARDPPARAPPARGS1PR4
SCHEMBL15037260 0.91 GPR132 (0.55) PPARDPPARAPPARGSMPD1PTPN1
SCHEMBL15037262 0.90 TPH1 (0.61) TPH1PPARDPPARAPPARGS1PR4
SCHEMBL15037113 0.90 TPH1 (0.51) MCHR1TPH1PPARDPPARAPPARG
SCHEMBL15037264 0.89 PPARG (0.53) TPH1PPARDPPARAPPARGS1PR4
SCHEMBL15037115 0.88 KDM4E (0.51) TPH1S1PR4S1PR1S1PR5S1PR3
SCHEMBL22448929 0.88 S1PR4 (0.51) TPH1PPARDPPARAPPARGS1PR4
SCHEMBL22449192 0.88 MAPT (0.55) TPH1PPARDPPARAPPARGS1PR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3008056-B1 NOVEL GLP-1 RECEPTOR MODULATORS CELGENE INT II SARL (CH) 2020-12-09 — — EP disclosed
EP-2791112-B1 CARBOXYLIC ACID DERIVATIVES COMPRISING FOUR CYCLES ACTING AS GLP-1 RECEPTOR MODULATORS FOR THERAPY OF DISEASES SUCH AS DIABETES CELGENE INT II SÀRL (CH) 2020-09-23 — — EP disclosed
EP-3230276-B1 GLP-1 RECEPTOR MODULATORS CELGENE INT II SARL (CH) 2020-09-02 — — EP disclosed
US-10259823-B2 GLP-1 receptor modulators CELGENE INTERNATIONAL II SÀRL (CH) 2019-04-16 — — US disclosed
US-10034886-B2 GLP-1 receptor modulators CELGENE INTERNATIONAL II SÀRL (CH) 2018-07-31 — — US disclosed
US-10034886-B2 GLP-1 receptor modulators CELGENE INTERNATIONAL II SÀRL (CH) 2018-07-31 — — US disclosed
US-20180021346-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS LLC 2018-01-25 — — US disclosed
US-20170313717-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS LLC 2017-11-02 — — US disclosed
US-9795613-B2 GLP-1 receptor modulators CELGENE INTERNATIONAL II SÀRL (CH) 2017-10-24 — — US disclosed
US-9795613-B2 GLP-1 receptor modulators CELGENE INTERNATIONAL II SÀRL (CH) 2017-10-24 — — US disclosed
US-9187522-B2 GLP-1 receptor modulators RECEPTOS, INC. (US) 2015-11-17 — — US disclosed
US-20150038416-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS LLC 2015-02-05 — — US disclosed
US-20150038416-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS LLC 2015-02-05 — — US disclosed
US-20150011527-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS LLC 2015-01-08 — — US disclosed
WO-2014201172-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS, INC. (US) 2014-12-18 — — WO disclosed
US-8778923-B2 GLP-1 receptor modulators RECEPTOS, INC. (US) 2014-07-15 — — US disclosed
US-8778923-B2 GLP-1 receptor modulators RECEPTOS, INC. (US) 2014-07-15 — — US disclosed
US-20130178420-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS, INC. (US) 2013-07-11 — — US disclosed
US-20130178420-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS, INC. (US) 2013-07-11 — — US disclosed
WO-2013090454-A2 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS, INC. (US) 2013-06-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170313717-A1 NOVEL GLP-1 RECEPTOR MODULATORS GLP1R, GIPR, NPY1R MCHR1 125/4885TPH1 860/4885PPARD 310/4885
US-20180021346-A1 NOVEL GLP-1 RECEPTOR MODULATORS GLP1R, GIPR, NPY1R MCHR1 125/4885TPH1 860/4885PPARD 310/4885
US-20130178420-A1 NOVEL GLP-1 RECEPTOR MODULATORS GLP1R, GIPR, NPY1R MCHR1 129/4885TPH1 867/4885PPARD 300/4885
US-20150038416-A1 NOVEL GLP-1 RECEPTOR MODULATORS GLP1R, GIPR, NPY1R MCHR1 129/4885TPH1 867/4885PPARD 300/4885
US-10034886-B2 GLP-1 receptor modulators GLP1R, GIPR, GCGR MCHR1 144/4885TPH1 831/4885PPARD 253/4885
US-10259823-B2 GLP-1 receptor modulators GLP1R, GIPR, GCGR MCHR1 144/4885TPH1 831/4885PPARD 253/4885
US-20150011527-A1 NOVEL GLP-1 RECEPTOR MODULATORS GLP1R, GIPR, NPY1R MCHR1 125/4885TPH1 860/4885PPARD 310/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback